NYKODE THERAPEUTICS ASA: årsregnskap 2024 vs 2023
Shrank 31% on revenue
approved 2025-04-28; registry 2025-06-16; journal 2025 517418
Summary
What changed
Comparing Årsregnskap 2024 with 2023 for NYKODE THERAPEUTICS ASA. Revenue 13.36m NOK → 9.16m NOK (-31.5%). Net result -33.39m NOK → -38.48m NOK. Equity 174.8k NOK → 140.14m NOK.
On the constructive side: operating result improved; equity strengthened. Pressures included: revenue fell; net result weakened; cash fell.
Also worth watching: paid-in equity reduced; book investments changed. All figures are taken from the published annual accounts for NYKODE THERAPEUTICS ASA.
At a glance
Scorecard
What improved
-
↑
Operating result improved
Operating result -56.48m NOK → -45.75m NOK (op. margin -422.7% → -499.5%). Calculated
-
↑
Equity strengthened
Book equity 174.8k NOK → 140.14m NOK (equity ratio 0.1% → 89.8%). Calculated
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 13.36m NOK to 9.16m NOK (-31.5% YoY). Calculated
-
↓
Net result weakened
Net result -33.39m NOK → -38.48m NOK (net margin -249.9% → -420.2%). Calculated
-
↓
Cash fell
Bank deposits 161.54m NOK → 114.02m NOK (-29.4% YoY). Calculated
-
↓
Payroll up without matching revenue
Salary cost 18.33m NOK → 19.74m NOK (137% → 216% of revenue). Calculated
Things to notice
-
·
Paid-in equity reduced
Paid-in equity fell 141.63m NOK → 144.9k NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Book investments changed
Investment / intangible book value 4.32m NOK → 4.77m NOK. Reported fact